Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.45 |
| ▸ | NTSR2 | O95665 | 8/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 6/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Davunetide SCHEMBL239737 | 0.96 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| Davunetide SCHEMBL3689039 | 0.96 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| Davunetide SCHEMBL239736 | 0.96 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| Davunetide SCHEMBL19712227 | 0.96 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| SCHEMBL30777830 | 0.90 | XIAP (0.48) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| SCHEMBL30056720 | 0.88 | CALCRL (0.42) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| Hydrochloric Acid SCHEMBL30504557 | 0.88 | CALCRL (0.42) | XIAPAGTR2AGTR1CALCRLNTSR2 | |
| SCHEMBL14693963 | 0.86 | XIAP (0.53) | XIAPAGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL14693960 | 0.86 | XIAP (0.53) | XIAPAGTR2AGTR1NTSR2NTSR1 | |
| SCHEMBL29590984 | 0.84 | NTSR2 (0.49) | NTSR2NTSR1SORT1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292231-A1 | Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers | AJAMI ALFRED M | 2010-11-18 | — | — | US | disclosed |
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | XANTHUS PHARMACEUTICALS, INC. | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108641-A1 | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers | PMP22, PML, AQP4 | XIAP 696/4885AGTR2 2365/4885AGTR1 1821/4885 |
| US-20100292231-A1 | Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers | FLT3, CSF3R, CSF1R | XIAP 3006/4885AGTR2 3536/4885AGTR1 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.